First American Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

First American Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Sell	458 -2,019	-82%	-$941K	0.01%	269
2025 Q4	$1.12M	Sell	2,477 -484	-16%	-$209K	0.08%	146
2025 Q3	$1.16M	Sell	2,961 -8,387	-74%	-$3.51M	0.08%	135
2025 Q2	$5.05M	Sell	11,348 -5,663	-33%	-$2.61M	0.4%	78
2025 Q1	$8.25M	Buy	17,011 +514	+3%	+$240K	0.76%	40
2024 Q4	$6.64M	Sell	16,497 -20	-0.1%	-$9.27K	0.66%	52
2024 Q3	$7.68M	Sell	16,517 -2,275	-12%	-$1.09M	0.76%	45
2024 Q2	$8.81M	Buy	18,792 +971	+5%	+$421K	0.88%	38
2024 Q1	$7.45M	Buy	17,821 +521	+3%	+$220K	0.78%	42
2023 Q4	$7.04M	Sell	17,300 -5,689	-25%	-$2.1M	0.87%	43
2023 Q3	$7.99M	Sell	22,989 -529	-2%	-$185K	1.13%	31
2023 Q2	$8.28M	Buy	23,518 +805	+4%	+$271K	1.14%	26
2023 Q1	$7.16M	Buy	22,713 +1,022	+5%	+$307K	1.06%	34
2022 Q4	$6.26M	Buy	21,691 +860	+4%	+$262K	0.97%	40
2022 Q3	$6.03M	Buy	20,831 +858	+4%	+$247K	1.01%	36
2022 Q2	$5.63M	Buy	+19,973	New	+$5.35M	0.89%	46

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First American Trust's VRTX Position: Q1 2026 in Review

First American Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 82% in Q1 2026, selling an estimated $941K and leaving 458 shares worth $205K. The position accounts for 0.01% of the portfolio, ranked #269.

First American Trust first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $8.81M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

First American Trust held 458 shares of Vertex Pharmaceuticals worth $205K as of Q1 2026.
First American Trust sold 2,019 Vertex Pharmaceuticals shares in Q1 2026, an estimated $941K.
Vertex Pharmaceuticals made up 0.01% of First American Trust's portfolio in Q1 2026, its #269 holding.
First American Trust first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
First American Trust's Vertex Pharmaceuticals position peaked at $8.81M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on First American Trust's 13F filing for Q1 2026, filed 12 May 2026.